You just read:

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

News provided by

Kymera Therapeutics

Jun 19, 2019, 08:00 ET